R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
AbstractThis study examines the relationships between firm size, R&D costs and output in the pharmaceutical industry. Project-level data from a survey of 12 US-owned pharmaceutical firms on drug development costs, development phase lengths and failure rates are used to determine estimates of the R&D cost of new drug development by firm size. Firms in the sample are grouped into three size categories, according to their pharmaceutical sales at the beginning of the study period. The R&D cost per new drug approved in the US is shown to decrease with firm size, while sales per new drug approved are shown to increase markedly with firm size. Sales distributions are highly skewed and suggest that firms need to search for blockbuster drugs with above--average returns. The results are consistent with substantial economies of scale in pharmaceutical R&D, particularly at the discovery and preclinical development phases.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoArticle provided by Taylor & Francis Journals in its journal International Journal of the Economics of Business.
Volume (Year): 2 (1995)
Issue (Month): 2 ()
Contact details of provider:
Web page: http://www.tandfonline.com/CIJB20
Other versions of this item:
- Joseph A. Dimasi & Grabowski, Henry G. & Vernon, John, 1995. "R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry," Working Papers 95-16, Duke University, Department of Economics.
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology
- O32 - Economic Development, Technological Change, and Growth - - Technological Change; Research and Development; Intellectual Property Rights - - - Management of Technological Innovation and R&D
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
- Giuseppe Moscarini & Lones Smith, 1998.
"Wald Revisited: The Optimal Level of Experimentation,"
Cowles Foundation Discussion Papers
1176, Cowles Foundation for Research in Economics, Yale University.
- Giuseppe Moscarini & Lones Smith, 1998. "Wald Revisited: The Optimal Level of Experimentation," Working papers 98-4, Massachusetts Institute of Technology (MIT), Department of Economics.
- Finn Valentin & Henrich Dahlgren & Rasmus Lund Jensen, 2006. "Research Strategies in Science-based Start-ups - Effects on performance in Danish and Swedish biotechnology," DRUID Working Papers 06-11, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
- Schwartz, Eduardo S., 2002. "Patents and R& D as Real Options," University of California at Los Angeles, Anderson Graduate School of Management qt86b1n43k, Anderson Graduate School of Management, UCLA.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Michael McNulty).
If references are entirely missing, you can add them using this form.